Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics

Jessica Tay-Sontheimer, Laura M. Shireman, Richard P. Beyer, Taurence Senn, Daniela Witten, Robin E. Pearce, Andrea Gaedigk, Cletus L. Gana Fomban, Justin D. Lutz, Nina Isoherranen, Kenneth E. Thummel, Oliver Fiehn, J. Steven Leeder, Yvonne S. Lin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aim: We sought to discover endogenous urinary biomarkers of human CYP2D6 activity. Patients & methods: Healthy pediatric subjects (n = 189) were phenotyped using dextromethorphan and randomized for candidate biomarker selection and validation. Global urinary metabolomics was performed using liquid chromatography quadrupole time-of-flight mass spectrometry. Candidate biomarkers were tested in adults receiving fluoxetine, a CYP2D6 inhibitor. Results: A biomarker, M1 (m/z 444.3102) was correlated with CYP2D6 activity in both the pediatric training and validation sets. Poor metabolizers had undetectable levels of M1, whereas it was present in subjects with other phenotypes. In adult subjects, a 9.56-fold decrease in M1 abundance was observed during CYP2D6 inhibition. Conclusion: Identification and validation of M1 may provide a noninvasive means of CYP2D6 phenotyping.

Original languageEnglish (US)
Pages (from-to)1947-1962
Number of pages16
JournalPharmacogenomics
Volume15
Issue number16
DOIs
StatePublished - Dec 1 2014

Fingerprint

Cytochrome P-450 CYP2D6
Metabolomics
Biomarkers
Pediatrics
Dextromethorphan
Fluoxetine
Human Activities
Liquid Chromatography
Mass Spectrometry
Healthy Volunteers
Phenotype

Keywords

  • biomarker
  • clinical
  • CYP2D6
  • dextromethorphan
  • endogenous
  • fluoxetine
  • metabolomics
  • pediatric
  • phenotype

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Tay-Sontheimer, J., Shireman, L. M., Beyer, R. P., Senn, T., Witten, D., Pearce, R. E., ... Lin, Y. S. (2014). Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics, 15(16), 1947-1962. https://doi.org/10.2217/pgs.14.155

Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. / Tay-Sontheimer, Jessica; Shireman, Laura M.; Beyer, Richard P.; Senn, Taurence; Witten, Daniela; Pearce, Robin E.; Gaedigk, Andrea; Gana Fomban, Cletus L.; Lutz, Justin D.; Isoherranen, Nina; Thummel, Kenneth E.; Fiehn, Oliver; Leeder, J. Steven; Lin, Yvonne S.

In: Pharmacogenomics, Vol. 15, No. 16, 01.12.2014, p. 1947-1962.

Research output: Contribution to journalArticle

Tay-Sontheimer, J, Shireman, LM, Beyer, RP, Senn, T, Witten, D, Pearce, RE, Gaedigk, A, Gana Fomban, CL, Lutz, JD, Isoherranen, N, Thummel, KE, Fiehn, O, Leeder, JS & Lin, YS 2014, 'Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics', Pharmacogenomics, vol. 15, no. 16, pp. 1947-1962. https://doi.org/10.2217/pgs.14.155
Tay-Sontheimer J, Shireman LM, Beyer RP, Senn T, Witten D, Pearce RE et al. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics. 2014 Dec 1;15(16):1947-1962. https://doi.org/10.2217/pgs.14.155
Tay-Sontheimer, Jessica ; Shireman, Laura M. ; Beyer, Richard P. ; Senn, Taurence ; Witten, Daniela ; Pearce, Robin E. ; Gaedigk, Andrea ; Gana Fomban, Cletus L. ; Lutz, Justin D. ; Isoherranen, Nina ; Thummel, Kenneth E. ; Fiehn, Oliver ; Leeder, J. Steven ; Lin, Yvonne S. / Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. In: Pharmacogenomics. 2014 ; Vol. 15, No. 16. pp. 1947-1962.
@article{b5c179446397439fb082274037388d7f,
title = "Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics",
abstract = "Aim: We sought to discover endogenous urinary biomarkers of human CYP2D6 activity. Patients & methods: Healthy pediatric subjects (n = 189) were phenotyped using dextromethorphan and randomized for candidate biomarker selection and validation. Global urinary metabolomics was performed using liquid chromatography quadrupole time-of-flight mass spectrometry. Candidate biomarkers were tested in adults receiving fluoxetine, a CYP2D6 inhibitor. Results: A biomarker, M1 (m/z 444.3102) was correlated with CYP2D6 activity in both the pediatric training and validation sets. Poor metabolizers had undetectable levels of M1, whereas it was present in subjects with other phenotypes. In adult subjects, a 9.56-fold decrease in M1 abundance was observed during CYP2D6 inhibition. Conclusion: Identification and validation of M1 may provide a noninvasive means of CYP2D6 phenotyping.",
keywords = "biomarker, clinical, CYP2D6, dextromethorphan, endogenous, fluoxetine, metabolomics, pediatric, phenotype",
author = "Jessica Tay-Sontheimer and Shireman, {Laura M.} and Beyer, {Richard P.} and Taurence Senn and Daniela Witten and Pearce, {Robin E.} and Andrea Gaedigk and {Gana Fomban}, {Cletus L.} and Lutz, {Justin D.} and Nina Isoherranen and Thummel, {Kenneth E.} and Oliver Fiehn and Leeder, {J. Steven} and Lin, {Yvonne S.}",
year = "2014",
month = "12",
day = "1",
doi = "10.2217/pgs.14.155",
language = "English (US)",
volume = "15",
pages = "1947--1962",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "16",

}

TY - JOUR

T1 - Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics

AU - Tay-Sontheimer, Jessica

AU - Shireman, Laura M.

AU - Beyer, Richard P.

AU - Senn, Taurence

AU - Witten, Daniela

AU - Pearce, Robin E.

AU - Gaedigk, Andrea

AU - Gana Fomban, Cletus L.

AU - Lutz, Justin D.

AU - Isoherranen, Nina

AU - Thummel, Kenneth E.

AU - Fiehn, Oliver

AU - Leeder, J. Steven

AU - Lin, Yvonne S.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Aim: We sought to discover endogenous urinary biomarkers of human CYP2D6 activity. Patients & methods: Healthy pediatric subjects (n = 189) were phenotyped using dextromethorphan and randomized for candidate biomarker selection and validation. Global urinary metabolomics was performed using liquid chromatography quadrupole time-of-flight mass spectrometry. Candidate biomarkers were tested in adults receiving fluoxetine, a CYP2D6 inhibitor. Results: A biomarker, M1 (m/z 444.3102) was correlated with CYP2D6 activity in both the pediatric training and validation sets. Poor metabolizers had undetectable levels of M1, whereas it was present in subjects with other phenotypes. In adult subjects, a 9.56-fold decrease in M1 abundance was observed during CYP2D6 inhibition. Conclusion: Identification and validation of M1 may provide a noninvasive means of CYP2D6 phenotyping.

AB - Aim: We sought to discover endogenous urinary biomarkers of human CYP2D6 activity. Patients & methods: Healthy pediatric subjects (n = 189) were phenotyped using dextromethorphan and randomized for candidate biomarker selection and validation. Global urinary metabolomics was performed using liquid chromatography quadrupole time-of-flight mass spectrometry. Candidate biomarkers were tested in adults receiving fluoxetine, a CYP2D6 inhibitor. Results: A biomarker, M1 (m/z 444.3102) was correlated with CYP2D6 activity in both the pediatric training and validation sets. Poor metabolizers had undetectable levels of M1, whereas it was present in subjects with other phenotypes. In adult subjects, a 9.56-fold decrease in M1 abundance was observed during CYP2D6 inhibition. Conclusion: Identification and validation of M1 may provide a noninvasive means of CYP2D6 phenotyping.

KW - biomarker

KW - clinical

KW - CYP2D6

KW - dextromethorphan

KW - endogenous

KW - fluoxetine

KW - metabolomics

KW - pediatric

KW - phenotype

UR - http://www.scopus.com/inward/record.url?scp=84919788320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919788320&partnerID=8YFLogxK

U2 - 10.2217/pgs.14.155

DO - 10.2217/pgs.14.155

M3 - Article

C2 - 25521354

AN - SCOPUS:84919788320

VL - 15

SP - 1947

EP - 1962

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 16

ER -